Initial patient characteristics
| . | Dexamethasone* . | Prednisone* . |
|---|---|---|
| N (%) . | N (%) . | |
| Sex | ||
| Female | 803 (43.3) | 864 (46.3) |
| Male | 1050 (56.7) | 1003 (53.7) |
| Age (y) | ||
| ≥1 to <6 | 1147 (61.9) | 1127 (60.4) |
| ≥6 to <10 | 376 (20.3) | 402 (21.5) |
| ≥10 to <15 | 262 (14.1) | 252 (13.5) |
| ≥15 | 68 (3.7) | 86 (4.6) |
| Initial WBC (× 109/L) | ||
| <20 | 1200 (64.8) | 1182 (63.3) |
| 20 to <100 | 477 (25.7) | 505 (27.1) |
| ≥100 | 176 (9.5) | 180 (9.6) |
| CNS status | ||
| CNS negative | 1770 (97.5) | 1766 (97.1) |
| CNS positive | 46 (2.5) | 53 (2.9) |
| Immunophenotype | ||
| Precursor B | 1604 (87.8) | 1619 (88.3) |
| T | 220 (12.0) | 212 (11.6) |
| Other† | 2 (0.1) | 4 (0.2) |
| ETV6-RUNX1 | ||
| Positive | 405 (24.1) | 392 (22.8) |
| Negative | 1276 (75.9) | 1331 (77.2) |
| BCR-ABL | ||
| Positive | 35 (2.0) | 30 (1.7) |
| Negative | 1743 (98.0) | 1781 (98.3) |
| MLL-AF4 | ||
| Positive | 7 (0.4) | 13 (0.7) |
| Negative | 1718 (99.6) | 1747 (99.3) |
| DNA index | ||
| <1.16 | 1153 (81.1) | 1150 (80.8) |
| ≥1.16 | 268 (18.9) | 273 (19.2) |
| B-lineage NCI Risk criteria‡ | ||
| Standard risk | 1159 (72.3) | 1178 (72.8) |
| High risk | 445 (27.7) | 441 (27.2) |
| T-lineage NCI Risk criteria‡ | ||
| Standard risk | 61 (27.7) | 51 (24.1) |
| High risk | 159 (72.3) | 161 (75.9) |
| . | Dexamethasone* . | Prednisone* . |
|---|---|---|
| N (%) . | N (%) . | |
| Sex | ||
| Female | 803 (43.3) | 864 (46.3) |
| Male | 1050 (56.7) | 1003 (53.7) |
| Age (y) | ||
| ≥1 to <6 | 1147 (61.9) | 1127 (60.4) |
| ≥6 to <10 | 376 (20.3) | 402 (21.5) |
| ≥10 to <15 | 262 (14.1) | 252 (13.5) |
| ≥15 | 68 (3.7) | 86 (4.6) |
| Initial WBC (× 109/L) | ||
| <20 | 1200 (64.8) | 1182 (63.3) |
| 20 to <100 | 477 (25.7) | 505 (27.1) |
| ≥100 | 176 (9.5) | 180 (9.6) |
| CNS status | ||
| CNS negative | 1770 (97.5) | 1766 (97.1) |
| CNS positive | 46 (2.5) | 53 (2.9) |
| Immunophenotype | ||
| Precursor B | 1604 (87.8) | 1619 (88.3) |
| T | 220 (12.0) | 212 (11.6) |
| Other† | 2 (0.1) | 4 (0.2) |
| ETV6-RUNX1 | ||
| Positive | 405 (24.1) | 392 (22.8) |
| Negative | 1276 (75.9) | 1331 (77.2) |
| BCR-ABL | ||
| Positive | 35 (2.0) | 30 (1.7) |
| Negative | 1743 (98.0) | 1781 (98.3) |
| MLL-AF4 | ||
| Positive | 7 (0.4) | 13 (0.7) |
| Negative | 1718 (99.6) | 1747 (99.3) |
| DNA index | ||
| <1.16 | 1153 (81.1) | 1150 (80.8) |
| ≥1.16 | 268 (18.9) | 273 (19.2) |
| B-lineage NCI Risk criteria‡ | ||
| Standard risk | 1159 (72.3) | 1178 (72.8) |
| High risk | 445 (27.7) | 441 (27.2) |
| T-lineage NCI Risk criteria‡ | ||
| Standard risk | 61 (27.7) | 51 (24.1) |
| High risk | 159 (72.3) | 161 (75.9) |
Data refer to patients with successful investigation of the respective criteria.
Mature B-cell leukemia, cytomorphologically FAB L1 (n = 3), natural killer cell leukemia (n = 1), acute undifferentiated leukemia (n = 1).
NCI-SR, age ≥1 and <10 y and WBC <50 × 109/L; NCI-HR, age ≥10 y or WBC ≥50 × 109/L.